The use of mucoactive agents in paediatric intensive care

Every day in UK paediatric intensive care units, doctors prescribe mucus-thinning drugs to help children breathe, but no one knows which drugs work best or how they are actually being used. This matters because there is no standardised guidance for using these mucoactive medications in critically ill children. Doctors rely on adult studies, personal experience, or local habits, which means children may receive treatments that are ineffective or even harmful. The problem is that no one has systematically documented what is currently happening across the country. This observational study will take a snapshot of practice at 27 NHS paediatric intensive care units at four separate time points. Researchers will record which drugs are given, in what doses, and how they are administered to children aged 0–18 years. The data comes from routine hospital records, with no identifiable patient information. If this research succeeds, it will provide the first comprehensive map of current UK practice. That map can then guide the design of future clinical trials to test which mucoactive agents actually improve outcomes for sick children. The immediate impact is not a change in treatment, but a clear picture of what needs to change.